TherapeuticsMD – (NYSEMKT:TXMD)

Finance December 9, 2015

Key Stock Analysts at Jefferies Didn’t Change their ‘”Buy”’ rating for TherapeuticsMD (NYSEMKT:TXMD) Shares Today. Their TP Provided Is $18.0

TherapeuticsMD (NYSEMKT:TXMD) Rating Reaffirmed In recent note issued to clients on Tuesday morning, The “Buy” rating of TherapeuticsMD (NYSEMKT:TXMD) shares was kept steady by Jefferies,…

Finance December 9, 2015

Reaffirmed: TherapeuticsMD (NYSEMKT:TXMD) Buy Rating Reconfirmed by research analysts Stifel; $14.0 Target in Place

TherapeuticsMD (NYSEMKT:TXMD) Rating Reaffirmed Analysts at Stifel now has a $14.0 target price on TherapeuticsMD (NYSEMKT:TXMD). Stifel and their recent target price would possibly suggest…

Finance December 9, 2015

TherapeuticsMD (NYSEMKT:TXMD) Has Just Had Its Price Objective Upped by Investment Analysts at Guggenheim to $33.00

Stock Analysis:TherapeuticsMD (NYSEMKT:TXMD) Stock Target Has Been Increased In an analyst research report sent to investors by Guggenheim on Tuesday morning, TherapeuticsMD (NYSEMKT:TXMD) had its…